Spierenburg Geert, Verspoor Floortje G M, Wunder Jay S, Griffin Anthony M, Ferguson Peter C, Houdek Matthew T, King David M, Boyle Richard, Randall Robert Lor, Thorpe Steven W, Priester Jacob I, Geiger Erik J, van der Heijden Lizz, Bernthal Nicholas M, Schreuder Bart H W B, Gelderblom Hans, van de Sande Michiel A J
Department of Orthopedic Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Department of Orthopedic Surgery, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.
Cancers (Basel). 2023 Feb 2;15(3):941. doi: 10.3390/cancers15030941.
Diffuse-type tenosynovial giant cell tumors' (D-TGCTs) intra- and extra-articular expansion about the knee often necessitates an anterior and posterior surgical approach to facilitate an extensive synovectomy. There is no consensus on whether two-sided synovectomies should be performed in one or two stages. This retrospective study included 191 D-TGCT patients from nine sarcoma centers worldwide to compare the postoperative short-term outcomes between both treatments. Secondary outcomes were rates of radiological progression and subsequent treatments. Between 2000 and 2020, 117 patients underwent one-stage and 74 patients underwent two-stage synovectomies. The maximum range of motion achieved within one year postoperatively was similar (flexion 123-120°, = 0.109; extension 0°, = 0.093). Patients undergoing two-stage synovectomies stayed longer in the hospital (6 vs. 4 days, < 0.0001). Complications occurred more often after two-stage synovectomies, although this was not statistically different (36% vs. 24%, = 0.095). Patients treated with two-stage synovectomies exhibited more radiological progression and required subsequent treatments more often than patients treated with one-stage synovectomies (52% vs. 37%, = 0.036) (54% vs. 34%, = 0.007). In conclusion, D-TGCT of the knee requiring two-side synovectomies should be treated by one-stage synovectomies if feasible, since patients achieve a similar range of motion, do not have more complications, but stay for a shorter time in the hospital.
弥漫型腱鞘巨细胞瘤(D-TGCT)在膝关节周围的关节内和关节外扩展通常需要采用前后联合手术入路,以利于进行广泛的滑膜切除术。对于双侧滑膜切除术应分一期还是两期进行,目前尚无共识。这项回顾性研究纳入了来自全球九个肉瘤中心的191例D-TGCT患者,以比较两种治疗方法术后的短期疗效。次要结局指标为放射学进展率和后续治疗情况。在2000年至2020年期间,117例患者接受了一期滑膜切除术,74例患者接受了两期滑膜切除术。术后一年内达到的最大活动范围相似(屈曲123 - 120°,P = 0.109;伸展0°,P = 0.093)。接受两期滑膜切除术的患者住院时间更长(6天对4天,P < 0.0001)。两期滑膜切除术后并发症发生率更高,尽管差异无统计学意义(36%对24%,P = 0.095)。与接受一期滑膜切除术的患者相比,接受两期滑膜切除术的患者放射学进展更多,后续治疗需求也更频繁(52%对37%,P = 0.036)(54%对34%,P = 0.007)。总之,对于需要双侧滑膜切除术的膝关节D-TGCT,若可行,应采用一期滑膜切除术进行治疗,因为患者可获得相似的活动范围,并发症并不更多,但住院时间更短。